<div>
<p>Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. 	For the SPDR S&amp;P China ETF (Symbol: GXC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $124.19 per unit.</p><p>With GXC trading at a recent price near $92.21 per unit, that means that analysts see 34.69% upside for this ETF looking through to the average analyst targets of the underlying holdings.   Three of GXC's underlying holdings with notable upside to their analyst target prices are Legend Biotech Corp (Symbol: LEGN), Structure Therapeutics Inc (Symbol: GPCR), and VNET Group Inc (Symbol: VNET). Although LEGN has traded at a recent price of $19.14/share, the average analyst target is 216.78% higher at $60.63/share. Similarly, GPCR has 103.81% upside from the recent share price of $53.48 if the average analyst target price of $109.00/share is reached, and analysts on average are expecting VNET to reach a target price of $16.34/share, which is 99.55% above the recent price of $8.19. Below is a twelve month price history chart comparing the stock performance of LEGN, GPCR, and VNET:  

</p><p><img alt="LEGN, GPCR, and VNET Relative Performance Chart" src="https://imageproxy.pbkrs.com/https://secure.tickertech.com/pics/2026/538995617A1.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="340" original-src="https://imageproxy.pbkrs.com/https://secure.tickertech.com/pics/2026/538995617A1.gif"/>
</p><p>Below is a summary table of the current analyst target prices discussed above:

</p><p></p><section><table><tbody><tr> <th>Name</th> <th align="center">Symbol</th> <th align="right">Recent Price</th> <th align="right">Avg. Analyst 12-Mo. Target</th> <th align="right">% Upside to Target</th></tr><tr> <td><b>SPDR S&amp;P China ETF</b></td> <td align="center"><b>GXC</b></td> <td align="right"><b>$92.21</b></td> <td align="right"><b>$124.19</b></td> <td align="right"><b>34.69%</b></td></tr><tr> <td>Legend Biotech Corp</td> <td align="center">LEGN</td> <td align="right">$19.14</td> <td align="right">$60.63</td> <td align="right">216.78%</td></tr><tr> <td>Structure Therapeutics Inc</td> <td align="center">GPCR</td> <td align="right">$53.48</td> <td align="right">$109.00</td> <td align="right">103.81%</td></tr><tr> <td>VNET Group Inc</td> <td align="center">VNET</td> <td align="right">$8.19</td> <td align="right">$16.34</td> <td align="right">99.55%</td></tr></tbody></table></section><p>Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.  

</p><p>
<img height="16" src="https://imageproxy.pbkrs.com/https://www.dividendchannel.com/nslideshow.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="16" original-src="https://imageproxy.pbkrs.com/https://www.dividendchannel.com/nslideshow.gif"/> 10 ETFs With Most Upside To Analyst Targets »
</p><p>
</p><h5>Also see:</h5><p>
	 YTD Return<br/>
	 SMCI Videos<br/>
	 High Yield Stocks<br/>
</p>
<p>The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.</p>
</div>

LEGN

GPCR

VNET

<p>The SPDR S&P China ETF (GXC) has an implied analyst target price of $124.19, indicating a potential upside of 34.69% from its recent trading price of $92.21. Notable underlying holdings include Legend Biotech Corp (LEG), with a target price of $60.63 (216.78% upside), Structure Therapeutics Inc (GPCR) at $109.00 (103.81% upside), and VNET Group Inc (VNET) at $16.34 (99.55% upside). Analysts' optimism raises questions about the validity of these targets and the need for further investor research.</p>

nasdaq

We Did The Math GXC Can Go To $124